Skip to content Skip to navigation
National Cancer Data Base - Data Dictionary PUF 2014

Immunotherapy at This Facility

PUF Data Item Name: 
NAACCR Item #: 
Allowable values: 
00, 01, 82, 85-88, 99
Records the type of immunotherapy administered as first course treatment at the facility that submitted the record. If immunotherapy was not administered, then this item records the reason it was not administered to the patient.
Registry Coding Instructions: 

·         Code 00 if immunotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.
·         Code 00 if the treatment plan offered multiple options, and the patient selected treatment that did not include immunotherapy.
·         If it is known that immunotherapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
·         Code 87 if the patient refused recommended immunotherapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
·         Code 99 if it is not known whether immunotherapy is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered.
·         Refer to SEER*Rx ( for instructions for coding immunotherapy, chemotherapeutic and hormonal agents.

Update for 2013 PUF: Six drugs previously classified as Chemotherapy are now classified as BRM/Immunotherapy. This change in classification is effective only for cases diagnosed in January 1st, 2013 and forward. While the NCDB does not provide drug-specific data, changes in case counts may be observed for the Chemotherapy and Immunotherapy variables for cases diagnosed in 2013 due to the change in classification. The drugs are: Alemtuzumab/Campath, Bvacizumab/Avastin, Rituximab, Trastuzumab/Herceptin, Pertuzumab/Perjeta, and Cetuxumab/Erbitux.

NCDB System Code Assignments: 




None, immunotherapy was not part of the planned first course of therapy.  Diagnosed at autopsy.


Immunotherapy administered as first course therapy.


Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age).


Immunotherapy was not administered because the patient died prior to planned or recommended therapy.


Immunotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.


Immunotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.


Immunotherapy was recommended, but it is unknown if it was administered.


It is unknown whether a immunotherapeutic agent(s) was recommended or administered because it is not stated in patient record. Death certificate only.


Analytic Note: 

Immunotherapy is sometimes called biologic response modifier (BRM).
CoC cancer programs are required to identify treatment their patients received from all sources.  Immunotherapy may have occurred at any facility, or at multiple facilities, not limited to the one whose report is included in this file.